U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years... (114. Available at: A HREF http://www....)

HOME >> MEDICINE >> TECHNOLOGY

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

Date:4/8/2008

114. Available at:

http://www.fda.gov/cder/foi/appletter/2008/125057s114ltr.pdf. Accessed

March 10, 2008.

2 FDA Website. Approval History: sBLA 103795/1001. Available at:

http://www.fda.gov/cder/foi/appletter/1999/etanimm052799L.htm. Accessed

March 10, 2008.

3 Ravelli A. Juvenile Idiopathic Arthritis. The Lancet. 2007:369:767-778.

4 Medline Plus. Juvenile Rheumatoid Arthritis. US National Library of

Medicine, National Institute of Health. Available at

http://www.nlm.nih.gov/medlineplus/juvenilerheumatoidarthritis.html.

Accessed March 10, 2008.

5 Zeginni E. Association of HLA-DRB1*13 with susceptibility to uveitis in

juvenile idiopathic arthritis in two independent data sets.

Rheumatology. 2006;45:972974.

6 American College of Rheumatology Web site. Arthritis in Children.

Available at:

http://www.rheumatology.org/public/factsheets/arth_in_children.asp?aud=pat

Accessed March 11, 2008.

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
7. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
11. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

Post Your Comments:

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years...(114. Available at: A HREF http://www....),Health